(Q33400294)

26 July 2017

title

Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib (English)

1 reference

26 July 2017

1 reference

hepatocellular carcinoma

1 reference

Pascaline Boudou-Rouquette

inferred from title

author

3

Pascaline Boudou-Rouquette

0 references

Vincent Mallet

Vincent Mallet

7

0 references

Olivier Mir

Olivier Mir

1

0 references

Stanislas Pol

10

Stanislas Pol

1 reference

26 July 2017

8

Philippe Sogni

1 reference

26 July 2017

2

Romain Coriat

1 reference

26 July 2017

author name string

Pascaline Boudou-Rouquette

3

1 reference

26 July 2017

Stanislas Ropert

4

1 reference

26 July 2017

Jean-Philippe Durand

5

1 reference

26 July 2017

Anatole Cessot

6

1 reference

26 July 2017

Stanislas Chaussade

9

1 reference

26 July 2017

François Goldwasser

11

1 reference

26 July 2017

publication date

17 March 2012

1 reference

26 July 2017

1 reference

26 July 2017

volume

29

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

2793-2799

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-012-0208-x

26 July 2017

exact match

0 references

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Oxaliplatin: a review of preclinical and clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Definition and classification of cancer cachexia: an international consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Sarcopenia is predictive of nosocomial infection in care of the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0208-X

Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography

21 January 2018

1 reference

12 December 2020

Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function

1 reference

12 December 2020

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

12 December 2020

Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients.

1 reference

12 December 2020

10.1007/S12032-012-0208-X

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1027472752

0 references

1 reference